Summary: The aim of this study was to reveal the contribution of CYP4F2, CYP2C9, and VKORC1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of warfarin in Japanese pediatric patients. Genetic analyses of CYP4F2 (rs2108622), CYP2C9 (*2 and *3), and VKORC1 (¹1639G > A) were performed, and plasma unbound warfarin, vitamin K1 (VK1), and menaquinone-4 (MK-4) concentrations were determined in 37 Japanese pediatric patients. The patients with CYP4F2 variant alleles C/T and T/T scored significantly lower values for the warfarin sensitivity index (INR/Cpss) and had significantly higher plasma concentrations of MK-4 than patients with the CYP4F2 allele C/C. Moreover, the plasma MK-4 concentration was negatively correlated with the warfarin sensitivity index. In contrast, the VKORC1 genetic polymorphism did not influence the warfarin sensitivity index. In patients with the CYP2C9 *3 allele, the unbound oral clearance values (normalized to body surface area) for S-warfarin were found to be significantly lower than in patients with the wild-type allele. In conclusion, CYP4F2 genetic polymorphism and plasma MK-4 concentration influence the pharmacodynamics of warfarin, suggesting a mechanism though which CYP4F2 genotype affects warfarin dose.
Introduction
In pediatric patients, warfarin is the most commonly prescribed oral anticoagulant drug for the prevention and treatment of thromboembolic complications after mechanical valve replacement and the Fontan procedure. 1) It has been a challenge to extrapolate information obtained from drug studies on adult subjects to antithrombotic therapy in children. However, antithrombotic therapy in children differs from that in adults because of ongoing changes in physiology and pharmacological responses to the drug. Although warfarin has been used in pediatric patients over the past decade, little is known regarding the pharmacokinetic and pharmacodynamic relationship of warfarin in children. Warfarin has a narrow therapeutic range and its efficacy is highly variable between individuals. Therefore, it is essential to carry out a time-consuming procedure for monitoring the anticoagulant status using the international normalized ratio (INR) of prothrombin time to determine the adequate dosage for each patient. Although genetic and non-genetic factors have been demonstrated as causes of inter-individual variation in warfarin dosing for adults, there is limited information regarding the same in children. 2) Warfarin is clinically administrated as a racemic mixture of two enantiomers, S-warfarin and R-warfarin. It is suggested that S-warfarin has three to five times greater anticoagulant potency than R-warfarin. 3, 4) As S-warfarin is extensively metabolized to 7-hydoxywarfarin by the polymorphic CYP2C9 enzyme, variant alleles CYP2C9 *2 and CYP2C9 *3 give rise to large differences in the pharmacokinetics of S-warfarin compared with patients with the CYP2C9 *1/*1 genotype (wild type). 5) Warfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKORC1). Genetic variants in the VKORC1 gene have also been shown to influence the pharmacodynamics of warfarin and contribute to inter-individual variability of warfarin dosing. Studies from our lab and others have shown that CYP2C9 and VKORC1 genotypes and non-genetic factors (such as age and body weight) cumulatively predict approximately 30% of the variability in warfarin doses for adult patients. 2, [6] [7] [8] In addition to the CYP2C9 and VKORC1 polymorphisms, recent studies have reported a functional polymorphism in the CYP4F2 gene rs2108622 (V433M, C > T nucleotide substitution). The protein CYP4F2 catalyzes ½-hydroxylation of vitamin E, leukotriene B4, and arachidonic acid and has recently been identified as being responsible for the metabolism of vitamin K1 (phylloquinone, VK1) to hydroxyvitamin K1. [9] [10] [11] [12] Caldwell et al. reported that the CYP4F2 rs2108622 polymorphism contributes to warfarin dose requirements. Patients with the T/T genotype required approximately 1 mg/day more warfarin than those with the C/C genotype; corresponding to a 4-12% increase in the warfarin dose per T allele. 13) Borgiani et al. 14) and Takeuchi et al. 15) also demonstrated that the CYP4F2 rs2108622 polymorphism accounted for approximately 2-7% of the interindividual warfarin dose variability.
Besides these genetic factors, variability in vitamin K intake has been identified as a risk factor for the instability of oral anticoagulant therapies. [16] [17] [18] Vitamin K is a fat-soluble vitamin and a cofactor for £-glutamyl carboxylase (GGCX) in the vitamin K cycle. Vitamin K1 is synthesized and stored in various green vegetables, whereas vitamin K2 (menaquinones, MK-n) is produced by bacteria as well as intestinal microflora and is enriched in fermented foods. 19) MK-n has a variable side chain length of isoprene units, and n stands for the number of isoprenoid residues in the chain. Among the MK-n homologues, MK-4 is mostly found in food and is obtained from dietary VK1 and other MK-n in various animal tissues. 20) Although vitamin K is well known as an antagonist of warfarin, the degree to which vitamin K influences warfarin anticoagulant therapy has not been well established.
The aims of this study were 1) to confirm the effect of CYP4F2 and VKORC1 genotypes, and the CYP2C9 genotype, on the pharmacodynamics and the pharmacokinetics of warfarin, and 2) to evaluate the effect of plasma vitamin K (VK1 and MK-4) concentrations on the pharmacodynamics of warfarin in Japanese pediatric patients.
Methods
Patients: A total of 37 Japanese pediatric patients (<18 years) who received anticoagulation therapy with warfarin and demonstrated a stable anticoagulation status were recruited from the Shizuoka Children's Hospital. This study was approved by the ethics committee of the Shizuoka Children's Hospital and the University of Shizuoka, Shizuoka, Japan. All patients had received stable daily doses of warfarin for at least 1 month and had a stable anticoagulation status, which was determined from the results (within the therapeutic range) for a minimum of 3 consecutive INR measurements. Anticoagulant therapy was mainly intended for the prevention or treatment of thromboembolic diseases, such as mechanical valve replacement and the Fontan procedure. Written informed consent was obtained from either the patients or legal guardians after the purpose of the study was explained to them. Two milliliters of whole venous blood was collected into a tube containing EDTA-Na 2 . Whole blood was used to isolate genomic DNA, and plasma was harvested by centrifugation (1,500 © g for 10 min) to determine warfarin and vitamin K concentrations. Determination of the plasma unbound warfarin fraction was achieved by ultrafiltration (Centrifree YM-30, 30,000 molecular cut-off, Millipore, Milford, MA, USA) at 1,500 © g for 20 min at 37°C. A portion was stored at ¹70°C until analysis.
We also recorded demographic data (sex, age, body weight, and height) during blood sample collection. Body surface area (BSA) for each patient was obtained according to the equation of Du Bois et al.
21)
Genetic analyses of CYP4F2 (rs2108622), CYP2C9 (*2 and *3), and VKORC1 (¹1639G>A): Leukocyte genomic DNA was extracted directly from the blood specimens using a QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genetic analyses of CYP2C9 (*2 and *3) and VKORC1 (¹1639G > A) as previously described. 2, 22, 23) A PCR-RFLP method was used for genotyping CYP4F2 (rs2108622) based on the method reported by Cen et al. 24) In brief, genomic DNA (30-60 ng) was amplified in PCR buffer containing 200 µM dNTP mixture (Applied Biosystems, Foster City, CA, USA), 0.3 µM each of forward (5A-CCA GCC TTG GAG AGA CAG AC-3A) and reverse (5A-TGC CAC AGT GCC ACA CTA TT-3A) primers, 0.5 units HotStar Taq plus DNA polymerase (Qiagen), and 1.5 mM MgCl 2 . Amplification was performed using an iCycler thermal cycler (Bio-Rad, Hercules, CA, USA). The PCR conditions consisted of an initial denaturation/enzyme activation step at 95°C for 5 min, amplification for 30 cycles at 94°C for 15 s, 59°C for 20 s, and 72°C for 1 min and final extension at 72°C for 10 min. The amplified PCR products were digested with 3.0 units Pvu II (New England BioLabs, Beverly, MA, USA) at 37°C for 2 h and products were analyzed on a 3% agarose gel (agarose S, Nippon Gene, Tokyo, Japan).
Measurement of plasma unbound concentrations of warfarin: The concentration of warfarin enantiomers in the plasma was determined by HPLC-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) employing solid-phase extraction. In brief, 500 µL of 1% phosphoric acid solution in water and 10 µL deuterium-labeled warfarin (internal standard; warfarin-d5 at 100 ng/mL in methanol; Toronto Research Chemicals, North York, Ontario, Canada) were added to 50 µL plasma. This mixture was then applied to Oasis WCX cartridges (Waters, Milford, MA, USA) and pretreated with 1 mL methanol and 1 mL distilled water. The extract was washed with 1 mL of 5% ammonium solution in water. Warfarin enantiomers and internal standard were eluted with 500 µL methanol, which was evaporated to dryness under a stream of nitrogen at 40°C. The residue was dissolved in 50 µL mobile phase, and a 10-µL aliquot was injected into the HPLC column. Chiral separation was achieved using a Chirobiotic V column (5 µm, 250 © 4.6 mm, Astec) at room temperature, with an isocratic solvent system of 35:65 (v/v) acetonitrile/5 mM ammonium acetate (pH 5.0) and a flow rate of 0.5 mL/min. The lower limit for quantification of warfarin enantiomers in plasma was 0.25 ng/mL. At this concentration the coefficient of variation (CV) of the assay was generally 5-15%.
Measurement of plasma unbound concentrations of vitamin K: The plasma concentration of vitamin K (VK1 and MK-4) was measured using HPLC-atmospheric pressure chemical ionization tandem mass spectrometry (LC-APCI-MS/MS). 25) A 100-µL aliquot of plasma sample, 400 µL water, 100 µL of vitamin K1-d7 (internal standard; 1 ng/mL in ethanol; Toronto Research Chemicals), and 1.9 mL ethanol were placed into a 10 mL glass centrifuge tube and vortex-mixed for 1 min to precipitate the protein. The mixture was extracted with 5 mL of cyclohexane by vortex mixing for 10 min, and was centrifuged for another 5 min at 1,500 © g. The upper cyclohexane layer was removed and evaporated to dryness under a stream of nitrogen at 40°C. The residue was dissolved in 50 µL mobile phase, and a 20 µL aliquot was injected into the HPLC column. Separation was performed on a Kinetex C18 column (100 © 2.1 mm, 2.6 µm; phenomenex; Torrance, CA, USA). The mobile phase was methanol with 0.1% formic acid/water 98:2 (v/v), and the column temperature was maintained at 40°C. A constant mobile phase flow rate of 0.25 mL/min was employed throughout the analyses. The lower limit for quantification of VK1 and MK-4 in plasma was 100 pg/mL. At this concentrations the CV of the assay were generally 5-20%.
The LC-MS/MS system comprised an API 3000 triple quadrupole mass spectrometry (AB SCIEX) and Agilent HPLC system (Agilent Technologies). The following ESI interface parameters were used: nebulizer gas (NEB), 11 psi; curtain gas (CUR), 10 psi; ion spray voltage, ¹2,500 V; source temperature (TEM), 500°C; declustering potential (DP), ¹50 V; focusing potential (FP), ¹200 V; entrance potential (EP), ¹10 V; collision gas (CAD), 12 units; collision energy (CE), ¹28 eV; and collision cell exit potential (CXP), ¹8 V. Pharmacokinetic and pharmacodynamic analysis: The unbound oral clearance of R-and S-warfarin was determined using the equation (D/2¸)/Cpss, in which D/2 is the daily dose of the respective warfarin enantiomers,¸is the dosing interval (i.e., 24 h), and Cpss is the plasma unbound concentration of each warfarin enantiomer. It is assumed that warfarin bioavailability and patient compliance are complete. 15) We also calculated the INR response per warfarin plasma unbound concentration, termed the warfarin sensitivity index (INR/Cpss).
Statistical analysis: Differences between pairs of medians were determined using the non-parametric Mann-Whitney U test. A two-tailed p-value <0.05 was considered to be statistically significant. The relationship between the plasma vitamin K concentration and warfarin sensitivity index was tested using a linear regression model.
Results
Patient characteristics: A total of 37 Japanese pediatric patients were enrolled in this study. For CYP4F2, 20 patients (54.1%) had the C/C genotype, 16 patients (43.2%) had the C/T genotype and one patient (2.7%) had the T/T genotype. For VKORC1, 4 patients (10.8%) had the G/A genotype and 33 patients (89.2%) had the A/A genotype. Ninety-four percent of patients carried no variants allele for CYP2C9 (*1/*1, n = 35) and 5.4% carried one variant allele (*1/*3, n = 2). In this study, the patients were divided into two groups according to their CYP4F2 genotype ( Table 1) . There were no significant differences in the sex, age, weight, height, body surface area, or PT-INR between the two groups.
Effect of CYP2C9 genotype on warfarin clearance: Pharmacokinetic parameters for warfarin enantiomers and vitamin K (VK1 and MK-4) are summarized in Table 2 . Oral clearance values for S-warfarin, which was normalized to the body surface area, was 335 (321-407) mL/min/m 2 , median (95% confidence interval) in the CYP2C9 *1/*1 genotype group, 187 (119-251) mL/min/m 2 in the CYP2C9 *1/*3 genotype group, and 582 (246-1,149) mL/min/m 2 in the patients who were administered bosentan Each value represents the median (95% confidence interval). Data on plasma unbound warfarin concentration and unbound oral clearance of warfarin in patients with the C/C (n = 15), C/T or T/T (n = 14) genotypes (patients with CYP2C9 *1/*3 and patients co-administrated bosentan with warfarin were excluded). Asterisks indicate significant differences between the CYP4F2 genotype groups; *p < 0.05. with warfarin. Unbound oral clearance from the CYP2C9 *1/*3 genotype group was 44.8% less than the corresponding values obtained from the *1/*1 genotype group (Fig. 1) . Unbound oral clearance values for S-warfarin were 73.7% greater in the patients who were administered bosentan with warfarin compared with patients with the wild-type CYP2C9 *1/*1 genotype (p < 0.05). On the other hand, the body surface area-normalized warfarin dose was 2.31 (2.10-2.61) mg/m 2 /day, median (95% confidence interval) in CYP2C9 *1/*1 patients, 2.32 (¹3.67-8.31) mg/m 2 /day in CYP2C9 *1/*3 patients, and 1.94 (1.59-2.61) mg/m 2 /day in patients who were co-administered bosentan. These differences were not significant.
Effect of VKORC1 genotype on warfarin sensitivity: There was no significant difference observed in the warfarin sensitivity index, which was defined as the INR/warfarin plasma unbound concentration, between the VKORC1 G/A genotype and the A/A genotype (Fig. 2) .
Effect of CYP4F2 genotype on plasma vitamin K concentration and pharmacokinetic parameters of warfarin: Pharmacokinetic parameters for vitamin K (VK1 and MK-4) and warfarin enantiomers are summarized in Table 2 . In determining the CYP4F2 allele-dependent differences in the pharmacokinetics of vitamin K, patients with the CYP4F2 T allele (C/T and T/T) were shown to have a significantly higher plasma MK-4 concentration than those with only the CYP4F2 C allele (C/C). On the other hand, there were no significant differences in plasma VK1 concentration between CYP4F2 genotypes. Plasma unbound concentration and unbound oral clearance of S-and R-warfarin were not significantly different between the two CYP4F2 genotype groups.
Effect of CYP4F2 genotype on warfarin sensitivity and dose: The warfarin sensitivity indexes in patients with the CYP4F2 T allele were 25.4% lower than for those with the C allele (Fig. 3A) . In addition, patients with the CYP4F2 T allele required a 30.8% increased dose of warfarin for INR (dose/INR) than those with only the C allele (Fig. 3B) .
Relationship between plasma vitamin K concentration and warfarin sensitivity: There was no significant correlation between the warfarin sensitivity index and plasma VK1 concentration (Fig. 4A) . In contrast, we investigated the negative correlation between the warfarin sensitivity index and plasma MK-4 concentrations (Fig. 4B) .
Discussion
Since Caldwell et al. reported the clinical impact of the CYP4F2 genotype, several studies have revealed that CYP4F2 genetic Fig. 1 . Effect of CYP2C9 genotype on unbound S-warfarin clearance Data on unbound S-warfarin clearance in patients with *1/*1 (n = 29), *1/*3 (n = 2) genotypes (patients co-administrated bosentan with warfarin were excluded). Boxes indicate the median and inter-quartile ranges. Vertical lines above and below boxes indicate minimum and maximum values. Asterisks indicate significant differences between the CYP2C9 genotype groups; *p < 0.05. variants contribute to the required maintenance dose of warfarin. 13) In patients with CYP4F2 variant alleles C/T and T/T, warfarin sensitivity was found to be significantly lower than in patients with the wild-type allele C/C. Furthermore, the CYP4F2 genotype was correlated with the warfarin maintenance dose. These results suggested that the CYP4F2 genotype influences the pharmacodynamics of warfarin and contributes to warfarin dose requirements. In Japanese adult patients, Nakamura et al. recently found that the mean warfarin daily dose was 29.4% higher in patients with the CYP4F2 T allele than those with only the CYP4F2 C allele when the patients with the CYP2C9 *1/*3 genotype were removed. 26) The magnitude of the effect of CYP4F2 genotypes on the warfarin dose requirements seemed to be similar in the present study. Singh et al. also found that the CYP4F2 C/T and T/T genotypes required a 25% higher warfarin dose than the CYP4F2 C/C genotype among Asian adult patients. 27) In addition, Nakamura et al. reported the influences of CYP4F2 genotype on serum R-warfarin concentration. 26) Lee et al. also reported that the CYP4F2 genotype could be attributed to not only warfarin sensitivity, but also to plasma S-and R-warfarin clearance. 28) However, in the present study we demonstrated only the contribution of the CYP4F2 genotype to the pharmacodynamics of warfarin. We evaluated the effect of plasma vitamin K on the pharmacodynamics of warfarin to reveal the mechanism by which CYP4F2 genotype affects warfarin dose requirements.
We found that the CYP4F2 genotype affects the plasma concentration of MK-4 and is correlated with the warfarin sensitivity index. These findings suggest that MK-4 may play a role in the relationship between warfarin sensitivity and CYP4F2 genotype. A specific human enzyme that converts the CYP4F2 metabolite VK1 to MK-4 has recently been described, thereby offering a mechanism for these observations. 29) Compared to other fat-soluble vitamins, vitamin K has large inter-and intra-individual variation in its intake and corresponding concentrations in the circulation. 30) In the present study, there was significant interindividual variability in the plasma concentrations of VK1 but not MK-4. Therefore, our study failed to demonstrate a relationship between CYP4F2 genotype, VK1 plasma concentration, and warfarin sensitivity.
The present data extend knowledge of the association between CYP2C9 genotype and the pharmacokinetics of warfarin. We observed significant differences in body surface area-normalized unbound oral clearance values for S-warfarin between patients with the CYP2C9 *1/*3 genotype and the wild-type genotype. Recently, Sangviroon et al. reported that CYP2C9 polymorphisms affect warfarin metabolism, showing significant differences in warfarin clearance in Asian adult patients. 31) In contrast, Nowak-Göttl et al. reported that the CYP2C9 and VKORC1 genotypes account for only 0.4% and 3.7% of variation, respectively, in the dose of vitamin K antagonists in pediatric patients. 32) In addition, this report concluded that age is the most significant variable in determining vitamin K antagonist dosing in children. Similarly, in the present study, the CYP2C9 and VKORC1 genotypes did not influence warfarin dosage. Thus, we investigated the association between body surface area-normalized warfarin dose and plasma S-warfarin concentration in patients with the CYP2C9 *1/*1 genotype and found no correlation between these variables (data not shown). As previously reported, these data suggested that weight-normalized pharmacokinetic parameters might not be a good index for the developmental changes in the pharmacokinetics of warfarin. 33) We also confirm that the unbound oral clearance values for S-warfarin in patients who were co-administered bosentan with warfarin were higher than in wild-type CYP2C9 *1/*1 patients. Bosentan was developed as an oral endothelin-1 receptor antagonist and is known as inducer of CYP2C9 and CYP3A4 isoenzyme systems. 34, 35) Several reports have described the pharmacokinetic interactions of bosentan and warfarin. 36, 37) However, in the present study the warfarin dose was not influenced by the administration of bosentan.
We have previously reported the contribution of VKORC1 genotype, body weight, age, and serum albumin to warfarin maintenance dose requirements in Japanese adult patients.
2) Associations between polymorphisms in the VKORC1 gene, warfarin dose, and risk of bleeding complications are being addressed by an increasing number of investigations. Our results show that in pediatric patients undergoing anticoagulant therapy, genotypes VKORC1 A/A and VKORC1 G/A did not statistically affect the warfarin sensitivity index. Recently, Moreau et al. demonstrated that height and the VKORC1 genotype (¹1639G > A) were the main determinants of warfarin dose requirements in 83 pediatric patients. 38) In this report, height and the VKORC1 genotype accounted for 48.1% and 18.2% of warfarin dose variability, respectively. Kato et al. have shown that VKORC1 genotype (1173C > T) and age were the major factors influencing the relationship between the weight-normalized warfarin dosage and therapeutic PT-INR values in Japanese pediatric patients. 39) Moreover, in Japanese patients (12-34 years old; median 22), Kosaki et al. found that the VKORC1 1173C/T genotype required higher INR normalized warfarin doses than the 1173T/T genotype.
40) It might be necessary to evaluate more patients with the VKORC1 (¹1639G > A) G allele to study the contribution of VKORC1 genotype in this study.
The purpose of this study was to evaluate the effects of CYP4F2, CYP2C9, and VKORC1 genotype on the pharmacokinetics and pharmacodynamics of warfarin in Japanese pediatric patients. We were only successful in recruiting 37 pediatric patients with an anticoagulation status stableized by warfarin to this study since the clinical trial was conducted at a single medical center. Nevertheless, we obtained very interesting results on the CYP4F2 genotype. To our knowledge, this is the first report demonstrating a quantitative influence of vitamin K, especially MK-4, on warfarin anticoagulation therapy in Japanese pediatric patients.
In conclusion, the present study confirmed the contribution of CYP4F2 genotype to the pharmacodynamics and dose variability of warfarin.
